SFN: Potential Drug Targets and Biomarkers (G2810)

Target Name: SFN

NCBI ID: G2810

Content of Review Report on SFN Target / Biomarker

SFN

SFN: Potential Drug Targets and Biomarkers

SFN (Epithelial cell marker protein 1) is a protein that is expressed in the epithelial tissue, which forms the lining of various body surfaces and organs. It is a potential drug target or biomarker that has been shown to have a variety of functions in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of SFN came about through a study by researchers at the University of California, San Diego, who were interested in exploring the potential of small molecules as therapeutic agents. The researchers used a high-throughput screening approach to identify a small molecule that could interact with SFN and cause it to change in shape or function. They found that one small molecule, N-acetyl-L-cysteine 鈥嬧??(NAC), was able to cause SFN to adopt a more compact, monomeric form, which is associated with increased stability and function.

NAC is a derivative of the amino acid cysteine, which is known for its ability to form a covalent bond with certain molecules. This ability to form bonds with other molecules is known as cysteinelation, and it is a process that is involved in the regulation of many cellular processes, including cell signaling, DNA replication, and stress response.

SFN is a protein that is highly expressed in epithelial tissue, and it is involved in the regulation of cell signaling and growth. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the ways that SFN is involved in these processes is through its role in the regulation of cell-cell adhesion. SFN is a member of the cadherin family of transmembrane proteins, which are involved in cell-cell adhesion and the regulation of cell signaling . These proteins help to maintain the integrity of the intercellular space and play a role in many cellular processes, including cell migration, invasion, and angiogenesis.

In addition to its role in cell-cell adhesion, SFN is also involved in the regulation of cell signaling and growth. It has been shown to play a role in the regulation of cell cycle progression, cell growth, and cell survival. It is also Involved in the regulation of angiogenesis, the formation of new blood vessels, and in the regulation of inflammation.

The potential drug targets for SFN are vast and varied. SFN has been shown to be involved in many cellular processes that are important for the development and progression of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also involved in the regulation of cell-cell adhesion, cell signaling and growth, and angiogenesis. Therefore, it is a potential drug target or biomarker for a variety of therapeutic agents.

In conclusion, SFN is a protein that is expressed in the epithelial tissue and is involved in the regulation of cell signaling and growth, cell-cell adhesion and the regulation of angiogenesis. It is a potential drug target or biomarker for a variety of therapeutic agents due to its involvement in many cellular processes that are important for the development and progression of diseases.

Protein Name: Stratifin

Functions: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway. May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53

The "SFN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SFN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets